Social Media Influencers Driving Parallel Market for Unlicensed Slimming Drug
A shadow economy for unapproved slimming medications is being driven by social media fitness personalities and sellers on communication apps, based on new investigations.
Investigational Drug Gaining Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being promoted by social media influencers for its alleged weight-reducing properties. Followers are urged to contact these accounts directly for supplier links, while also receiving discount codes.
Active Trade on Social Networks
Additionally, a robust market exists on messaging services, where communities with thousands of members share “before and after” photos, injection guides and claims of rapid UK delivery. Sellers promote the substance there before directing customers to WhatsApp for purchases.
Learning About Retatrutide
Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the substance is being promoted online as the successor to Ozempic.
Healthcare Professionals Express Worries
However, doctors and chemists have warned that the sale of what remains an unlicensed medication in the UK is worrisome and could result in users injecting products of uncertain source.
Some professionals stated the demand for retatrutide could be linked to the rising price of approved weight loss treatments such as Mounjaro.
Legal Status and Enforcement
Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.
Several influencers try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate pharmaceutical, advertising, and consumer regulations, risking fines, prosecution or imprisonment.
Service Response and Content Elimination
Based on the social media company, the platform has removed problematic content and prohibited related keywords and query recommendations. The organization stated it was committed to maintaining the service safe and allocating resources in strengthening enforcement strategies.
Digital Trading Operations
Investigations also discovered groups with up to 9,000 participants selling the experimental drug using Telegram's built-in discovery tool, which functions like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of users, populated with images of slimming results, glowing reviews and step-by-step guides for mixing or administering at residence.
After minutes of entering one community, a seller posted WhatsApp details, where most transactions occur. The vendor provided an guidebook and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about body mass, medical conditions or previous experience.
Item Information and Costs
Inside these communities, messages display black plastic parcels with Royal Mail labels, claiming to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled injectors usually priced at £160 for 20 milligrams. When asked how long a pen should last, sellers give conflicting answers ranging from a several days to “depends on your body”.
Service Moderation and Security Measures
A representative for the messaging service stated it regularly monitored dangerous material on its service including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are injecting materials they can’t verify. Even if the science behind this drug is sound, these digital products may not contain what they claim,” said Jason Murphy, the director of pharmacy at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the increase in interest to recent price rises for authorized slimming medications such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she explained.
Her team has already seen patients harmed by personal administration from unconfirmed sources. “We recognize the disappointment, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be contaminated or improperly measured.”
Producer Position
A spokesperson from the pharmaceutical company stated retatrutide was in third stage research studies and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any product “misleadingly claiming itself as a company investigational product not yet authorized … may subject patients to possibly significant health risks”.
